Verana Health Introduces New AI Agents to Expedite and Streamline R&D

Agent Claire for Life Sciences empowers researchers with conversational access to disease-specific real-world databases

SAN FRANCISCO, Sept. 24, 2026 /PRNewswire/ -- Verana Health^®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced the release of new artificial intelligence (AI) agents to aid researchers. Agent Claire for Life Sciences, available in disease-specific versions, enables researchers to rapidly generate analytic insights. Researchers can query the rich real-world datasets using conversational questions that range in sophistication. Leveraging specialized clinical training, the agent formulates execution plans and evaluates them against embedded clinical guardrails. With Agent Claire for Life Sciences, researchers have immediate, direct access to extensive data, without needing programming skills or analyst assistance.

Available across Verana Health RWD datasets in oncology, ophthalmology, and urology, Agent Claire empowers brand managers, medical affairs, market access teams, and HEOR professionals to ask questions and get answers in minutes, complete with patient distributions, treatment patterns, and outcomes data. Hypotheses that previously took days or weeks to explore are now available on-demand to the people who need it most.

"AI agents represent a shift away from tools that simply follow instructions, toward systems that help integrate information and guide next steps," said Sujay Jadhav, CEO of Verana Health. "As healthcare grows more complex, we're proud to broaden and amplify our capabilities for the life sciences community with AI agents that help navigate and interpret clinical information, offering context and guidance when teams need it most, so researchers can gain speed with confidence."

Access to Agent Claire aids in the compression of R&D cycles, allowing researchers to quickly identify patient populations of interest, verify that sufficient patient volume and data quality exist for cohort analyses, and ask clinical outcomes questions directly. Researchers get evidence-backed answers in minutes instead of weeks, complete with SQL output ready for data scientist validation.

For example, a researcher assessing therapies for multiple myeloma may want to run numerous queries:

• "How many patients received at least one line of therapy?"
• "Of these patients, how many received CAR-T therapy?"
• "What are the names of these CAR-T therapies and their frequency of use?"

Additionally, researchers can prompt the agent with a high level objective, such as "map the treatment progression for multiple myeloma patients moving from first-line therapy to CAR-T." The agent will then construct a step-by-step query strategy, laying out its analytic logic across each phase of the patient's treatment journey so users can review, refine, or run the queries as needed.

For research organizations that increasingly rely on real-world evidence for commercial strategy, medical planning, and launch decisions, Agent Claire allows more people across the organization to directly ask better questions, and get faster answers.

Beyond time-saving benefits, Agent Claire enables transparency and ensures scientific rigor because it is built on high-quality, robust datasets and every answer includes the underlying query logic. This gives teams the confidence to act on results and share them internally. Non-technical users can iterate freely, refining hypotheses, filtering cohorts, switching disease areas without technical bottlenecks. Verana's evaluation framework ensures alignment with validated queries and appropriate cautionary guidance when navigating more complex analyses. Agent Claire integrates into an organization's existing clinical infrastructure—strengthening governance, validation, and clinical expertise required for research.

"We are shifting from a paradigm of digital augmentation to one of AI agent integration across our core operations," said Chief Digital & Technology officer, top-5 global pharma. "Rather than requiring users to master multiple analytics tools and data sources, AI agents can accelerate, automate, and scale hypothesis testing across disciplines. Effectively leveraging these agents will provide us with a significant competitive advantage in speeding up our global development timelines and bringing effective treatments to patients more quickly."

Agent Claire is built for interoperability, designed to operate with industry leading AI agents (e.g., Claude by Anthropic, Google Gemini, Microsoft Copilot and others) using the open standard, Model Context Protocol (MCP). This connectivity allows users to have a streamlined experience, interacting with their organization's AI agent of choice, while calling Agent Claire and its trained clinical knowledge in the background.

According to McKinsey & Company, Life Sciences agents will boost clinical development productivity by 35-45% by 2030, and unlock $60-110B+ in annual revenue across pharma operations.

To learn more, visit veranahealth.com or the Verana Health Booth 2301 at the AAO 2026 Annual Meeting in New Orleans, Louisiana, October 9-12. To schedule a meeting in advance of the event, click here.

About Verana Health 

Verana Health, Inc.^® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.

SOURCE Verana Health